MedTech PR Strategy: What the UK's Most Watched Companies Do

The MedTech companies commanding the most attention in the UK in 2026 aren't necessarily the ones with the biggest budgets; they're the ones whose PR strategy centres on clinical credibility, regulatory timing, and earned trust with NHS decision-makers rather than broadcast volume.

Why is MedTech PR in the UK a distinct discipline?

MedTech communications in the UK differ from other forms of corporate B2B PR because companies in this sector undergo greater scrutiny from regulatory bodies, journalists, and clinical buyers. Generic PR strategies lack a foundation in specialist knowledge and are usually ill-equipped to navigate the unique opportunities and constraints this environment produces.

For example, MedTech communications have to operate within time constraints that don't apply to most B2B sectors.

Timing.

One of these constraints takes the form of the MHRA's post-Brexit regulatory framework. In most corporate B2B communications, the only concrete regulatory concern is whether product claims comply with advertising standards.

But MedTech companies also have to account for evolving accreditation roadmaps and time public communications against regulatory status. A broadcast-first strategy risks circulating premature claims that a product is 'MHRA-approved' or 'UKCA-marked' before official sign-off, which can severely damage credibility.

The target audience for MedTech communications also differs.

Audience.

NHS procurement decisions are shaped by NICE technology appraisals, integrated care board (ICB) commissioning priorities, and the NHS England MedTech funding mandate. Rather than targeting the general public, as most PR strategies do, effective MedTech communications are tailored to a professional audience of clinicians, commissioners, and procurement leads.

The policy backdrop for MedTech communications is uniquely important.

Policy.

Successful MedTech PR strategies actively reference ongoing policy debates to signal alignment with national priorities. This includes the Life Sciences Vision (2021), which sets out the government's ambitions for the sector over the next decade.

Again, national alignment isn't a consideration for most corporate B2B sectors, and it's something that generic PR strategies tend to overlook.

Building clinical credibility before the media campaign.

The most effective MedTech PR strategies in 2026 aim to build clinical credibility from day one. They generate a body of peer-reviewed evidence early, making it easier for health journalists and procurement teams to validate product claims. Companies that initially overlook this step to free up time and resources risk undermining their earned media efforts down the line.

So, how do MedTech companies build credibility?

Building an evidence base from the outset that satisfies the NICE Evidence Standards Framework is crucial, but MedTech companies also need to develop a credible clinical profile. This is done through:

• Publication in peer-reviewed journals, including The Lancet and the BMJ. Communications teams should be involved in the timing and amplification of these publications to maximise impact; PR strategies are less effective when they're brought in after the fact.
• Key Opinion Leader (KOL) relationships with NHS clinicians and Health Innovation Networks (HINs). Formerly known as Academic Health Science Networks, HINs help health professionals find and implement new ways to deliver care; they signal credibility to ICB commissioners and can help MedTech companies reach new buyers. This is akin to the 'influencer layer' in most corporate PR strategies.
• Royal College endorsements and active presence at clinical conferences. Maintaining a spokesperson presence at key events, including HETT and NHS ConfedExpo, helps to build a clinical profile and signals credibility to NHS procurement leads. Clinical spokespeople should undergo tailored media training to help prepare them for public-facing events.

It's important to recognise the difference between regulatory approval communications and an earned media strategy. The former is mostly a compliance exercise, operating on external timelines set by the regulator. Earned media strategy, in contrast, seeks to influence a broader audience on a self-determined schedule. They are distinct mechanisms and shouldn't be conflated in the planning stage.

The regulatory moment as a media hook.

The most-watched MedTech companies in the UK deliberately structure their PR strategies around key regulatory and reimbursement milestones to maximise coverage in the trade press. This approach consistently outperforms reactive communications, which are often too slow to capitalise on time-sensitive media opportunities.

So, what does this approach look like in practice?

• Preparing media content in advance of regulatory milestones. You can usually find appraisal time frames online; for example, NICE sets out a week-by-week timeline for its Single Technology Appraisal process. A company with a media plan ready for the day of a positive result will draw substantially more coverage than one that responds reactively.
• Planning concurrent regulatory wins. If a MedTech company successfully gains a positive NICE appraisal and UKCA/CE marking within a short time frame, this creates a dual news hook that attracts more coverage in UK trade media, including target publications such as Health Service Journal and Digital Health News.
• Co-authoring ICB-level adoption announcements with NHS trusts. These announcements increasingly appear in regional media and local NHS communications, and are an effective way to build a MedTech company's digital profile and credibility.

What are the most watched companies doing differently in 2026?

The most watched MedTech companies in 2026 prioritise clinical credibility, regulatory timing, and earned trust with NHS decision-makers. Practically, they share a handful of habits that you can replicate within your own communications strategy:

• Integrating regulatory affairs, clinical affairs, and communications functions into a single workstream.
• Running proactive media engagement with specialist health journalists.
• Investing in owned channels as a complement to, not a replacement for, earned media.

In contrast, MedTech companies that wait until after regulatory and clinical decisions are made to bring in an external communications team leave them little room to shape timing and messaging successfully. This limits the impact of any given media campaign and will ultimately produce fewer sales.

For your next read, find out how MedTech companies are building influence through thought leadership in 2026.